ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat

AbbVie (ABBV) reported robust third-quarter earnings, surpassing revenue expectations with $15.8 billion (up 9.1% year-over-year) and delivering adjusted EPS of $1.86, despite a significant R&D-related impact. The company raised its full-year adjusted EPS guidance to $10.61-$10.65, driven by strong performance from new blockbuster drugs Skyrizi and RINVOQ, which now account for approximately 50% of revenue and are effectively offsetting the decline in HUMIRA sales. This financial strength, combined with a robust drug pipeline and an 83% adjusted gross margin, positions AbbVie for continued growth, leading analysts like Piper Sandler to raise price targets to $284, while the company also increased its dividend by 5.5% to $1.73 per share, maintaining its 'Dividend King' status.

Analysis

AbbVie (ABBV) reported a strong third quarter, exceeding revenue expectations with $15.8 billion, a 9.1% year-over-year increase, and adjusted EPS of $1.86, beating estimates of $1.77. While adjusted EPS showed a 38% year-over-year decline, this was primarily due to a $1.50 per share impact from R&D expenses related to acquired intellectual property. The company subsequently raised its full-year adjusted EPS guidance to a range of $10.61-$10.65, signaling confidence in future performance.

Key growth was driven by new blockbuster drugs Skyrizi ($4.7 billion) and RINVOQ ($2.2 billion), which collectively now comprise approximately 50% of total net revenues, effectively mitigating the impact of declining HUMIRA sales following its 2023 patent loss. AbbVie's robust pipeline across immunotherapy, oncology, neuroscience, and aesthetics, combined with an adjusted gross margin exceeding 83% and R&D at 14.3% of net revenues, positions it for sustained growth into the next decade.

Analyst sentiment is bullish, with MarketBeat's consensus price target at $234.80 and Piper Sandler raising its target to $284, indicating significant upside potential. Furthermore, AbbVie reinforced its commitment to shareholder returns by increasing its dividend by 5.5% to $1.73 per share, maintaining its status as a "Dividend King" with 54 consecutive years of increases.

Key Decisions for Investors

• Consider initiating or increasing long positions in ABBV, given the strong Q3 performance, raised guidance, and successful diversification away from HUMIRA.
• Monitor the continued ramp-up of Skyrizi and RINVOQ sales, as well as progress in the extensive drug pipeline, for sustained revenue growth.
• Evaluate ABBV as a core holding for income-focused portfolios due to its consistent dividend growth and "Dividend King" status, alongside its growth prospects.